2Taniguchi M, Kawabata M. KIR3DL1/S1 genotypes and KIR2DS4 allelic variants in the AB KIR genotypes are associated with Plasmodium- posi- tiveindividualsinmalariainfection[J]. Imrnunogenetics, 2009,61 ( 11 - 12) : 717 -730.
3McMahon BJ. The natural history of chronic hepatitis B vires infection[J]. Hepatology, 2009,49 : S45 - S55.
4Wasley A, Kruszon- Moran D, Kuhnea W, et al. The prevalence of hep- atitis B virus infection in the United States in the era of vaccination[J]. J Infect Dis,2010,202(2) : 192 - 201.
5Hall AJ. Boosters for hepatitis B vaccination Need for an evidence - based policy[J]. Hepatology,2010,5 ( 1 ) : 1 485 - 1 486.
6Xu DZ. Zhe CK, Guo LM, et al. A randomized controlled phase Ibtrial o- fantigen- antibody immunngenic complex theraputie vaccine in chronic hepatitis B patients[J]. Plo S One,2008,3(7) :e2 565.
7Center for Disease Prevention and Control. Breastfeeding[EB/OL] . [2010 - 12 -8] . http://www, cdc. gov/ breastfeeding/disease/hepatitis, htm.
8Floreani A, Baldo V, Cristofoletti M, et al. Long - term persistence of an- ti - HBs after vaccination against HBV : an 18 year experience in health care workers[J]. Vaccine ,2004,22 (5 -6) :607 -610.
9Lin CS, Xie SB, Liu J, et al. Efect of revaccination using diferent schemes among adults with low or undetectable anti - HBs titers after hepatitis B virus vaccination [J]. Clinical and Vaccine Immunology, 2010, 17 (10) : 1 548-1551.
10Playford EG, Hogan PG, Bansal AS, et al. Intradermal recombinant hep- atitis B vaccine for healthcare workers who fail to respond to intramuscu- lar vaccine [ J ]. Epidemiology, 2002,23 (2) : 87 - 90.
